CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial Translational Perspective on Epigenetics in Cardiovascular Disease Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media High-Risk Coronary Atherosclerosis Is It the Plaque Burden, the Calcium, the Lipid, or Something Else? Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Future of Personalized Cardiovascular Medicine Classification of Deaths in Cardiovascular Outcomes Trials Known Unknowns and Unknown Unknowns 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed

ConsensusNovember 2018

JOURNAL:J Am Coll Cardiol. Article Link

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways

Writing Committee, Sandeep RD, Brendan M et al. Keywords: ASCVD; cardiovascular risk reduction; diabetes; Expert Consensus; Decision Pathway; GLP-1RA; SGLT2 inhibitor; T2D

FULL TEXT PDF